TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06470178

Intervention type: COMBINATION_PRODUCT
Intervention: corhot1: chemotherapy combined with fruquintinib
Description: Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles.

Intervention type: COMBINATION_PRODUCT
Intervention: corhot2: chemotherapy combined with fruquintinib
Description: Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles.
Study: NCT04846803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABU bladder lavage
Description: Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with the non-pathogenic bacterial strain (ABU)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline bladder lavage
Description: Clinical effect of preventive treatment (prophylactic treatment) - bladder lavage with saline
Study: NCT05435690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-assisted arthroplasty
Description: Computer-assisted arthroplasty
Study: NCT06490679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand and ultrasonic scalers and curettes
Description: Combination of ultrasonic and hand instrumentation only. Pockets ≥7 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electro Medical Systems AIRFLOW® Prophylaxis Master Device
Description: (a) Disclosure of biofilm with erythrosine, (b) Removal of supragingival and subgingival (up to 10 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS-Dental, Nyon Switzerland).~(c) Supra- and sub-gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology.
Study: NCT04668235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZVUDINE
Description: 5 tablets QD + standard treatment for up to 14 days
Study: NCT05298332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2173 50 mg
Description: ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2173 50 mg
Description: ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2173 50 mg
Description: ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)
Study: NCT05492331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patient preferred artist or music genre to be playing from an iPad
Study: NCT05914688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590 (Formulation 1)
Description: Administered SC.
Study: NCT04668235

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZVUDINE placebo
Description: 5 tablets QD + standard treatment for up to 14 days
Study: NCT05039008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: The intervention protocol will be carried out under the same environmental conditions and, as far as possible, at the same time. The intervention will last 4 weeks, with a periodicity of 3 weekly sessions. In total there will be 12 sessions that will last between 15 and 30 minutes depending on the number of joints affected.
Study: NCT05914688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590 (Formulation 2)
Description: Administered SC.
Study: NCT05835609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM534
Description: PM534 drug product is provided as a powder for concentrate for solution for infusion, is a sterile, preservative-free, lyophilized white cake in a single-dose vial for reconstitution prior to intravenous infusion.
Study: NCT04923087

Intervention type: DEVICE
Intervention: Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements
Description: Validate the evaluation criteria Do you hear the biscuit crunch? and Is it a pleasure?
Study: NCT05487326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: fascial plane injection guided by ultrasound guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical epidural injection
Description: cervical epidural injection by fluoroscopy
Study: NCT06399588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention for Adolescent Tobacco Initiation Prevention (IATIP)
Description: The IATIP is an evidence-based tobacco prevention program tailored for Bangladeshi adolescents, integrating Behavior Change Techniques, the Behavior Change Wheel, and the Theoretical Domains Framework. Utilizing the Arena Blended Connected (ABC) model ensures effective delivery. Six key learning types are integrated to optimize knowledge acquisition, concept exploration, collaboration, discussions, practical application, and skill development. The curriculum comprises three core components addressing adolescents' challenges: the information curriculum cultivates factual awareness, the social competence curriculum strengthens refusal skills and social competencies, and the social influence curriculum builds resilience against tobacco-promoting social influences.
Study: NCT06216314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate (HR)
Description: Runners ran according to speeds and HR associated with ventilatory thresholds. Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Race pace based approach (RP)
Description: Runners ran respecting three intensity zones.~The average speed achieved in the 7-km was calculated. From this, three intensity zones were calculated, adhering to the % of the race pace of the 7-km test.~Z1 corresponds to less than 80% of race pace, Z2 is between 80-95%, and Z3 corresponds to over 95% of race pace

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rate + heart rate variability (HRV)
Description: Runners completed training sessions based on HR values and velocities associated with ventilatory thresholds (i.e., Z1, zone 1: intensity zone below the first ventilatory threshold; Z2: zone 2, intensity zone between the first and second ventilatory threshold; Z3: zone 3, intensity zone above the second ventilatory threshold. The training sessions were based on physiological thresholds and daily HRV cues. High-intensity training was performed only under optimal HRV conditions, thus only when each participant had HRV values in their reference range. If HRV was not optimal, low-intensity training was prescribed. If HRV was not optimal for two days consecutively, rest was prescribed.
Study: NCT04682990

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tor Vergata Electronic Nose (TV eNose)
Description: Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tor Vergata Electronic Nose (TV eNose)
Description: Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey & Physical Exam
Description: Perform a oriented survey for risk factors, symptoms and a complete physical exam.
Study: NCT05608473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posture Exercises
Description: A 10-minute video consisted of 14 cervical and thoracal postural exercises was uploaded to the computers of the participants. Participants were asked to do these exercises simultaneously with the video, 3 days in a week for 6 weeks. During theese weeks, the participants were checked by sms and they were asked to keep an exercise diary. For progression, the number of repetitions was increased in the 3rd week and the number of sets in the 5th week.
Study: NCT04813783

Intervention type: OTHER
Intervention: Mucositis care training to be given in line with MASCC / ISOO 2019
Description: Mucositis care training to be given in line with MASCC / ISOO 2019
Study: NCT06133426

Intervention type: DEVICE
Group type: OTHER
Intervention: Connected scale Body Comp Pro from Withings
Description: Use once a day from inclusion to week 7.
Study: NCT06361121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mid-point transverse process to pleura (MTP) block
Description: the T1-T12 thoracic spinal levels will be sonographically identified using a high frequency linear US probe (HFL_50, 15_6MHz). Then the probe will be placed vertically and nearly 3 cm lateral to the spinous process at the thoracic level T4/T5. The paraspinal muscles (erector spinae, trapezius, rhomboid), transverse processes , superior costo-transverse ligament (SCTL) and parietal pleura will be all identified under parasagittal scanning.~In MTP block group, A 22G, 50mm block needle (SONOTAP,Pajunk, -Geisingen,Germany) will be inserted in the cranial to caudal direction via an in-plane approach between the 2 transverse processes and advanced till it reaches the mid-point between the transverse process and pleura. After negative aspiration of blood or air, a total volume of 20 ml of bupivacaine 0.25% ( not exceeding a maximum dose of 2 mg/kg) will be injected superficial to the SCTL.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: In the TPV block group , the transverse process and the pleura will be identified and the needle will be inserted in the cranial to caudal direction till it pierces the SCTL and reaches the paravertebral space. After negative aspiration of blood or air a total volume of 20 ml of bupivacaine 0.25% will be injected displacing the pleura downwards
Study: NCT05141617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment
Description: Patients in the endoscopic treatment receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: Patients in the TIPS group receive Transjugular Intrahepatic Portosystemic Shunt
Study: NCT04682990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey & Physical Exam
Description: Perform a oriented survey for risk factors, symptoms and a complete physical exam.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TB LAMP test
Description: Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TB LAMP test
Description: Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sputum Samples
Description: Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sputum Samples
Description: Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest X-Ray
Description: Perform anteroposterior chest X-ray (if required by the medical staff)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest X-Ray
Description: Perform anteroposterior chest X-ray (if required by the medical staff)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow Up 5 days after beginning of Tx.
Description: Following the usual planning of the center for Positive TB Patients, they will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow Up & 15 days after beginning of Tx.
Description: Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow Up & 30 days after beginning of Tx.
Description: Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment.
Study: NCT05003661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents' Voice
Description: the intervention is recording of parents voice of reading children's book.
Study: NCT05892042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 MG [Xarelto]
Description: Eligible subjects randomized into experimental group will receive rivaroxaban 15mg daily in addition to dual anti platelet therapy unless confirmed resolution of the left ventricular thrombus.
Study: NCT05430230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen 500 Mg
Description: naproxen tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen 500 Mg
Description: naproxen tablets
Study: NCT05788705

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: apigenin and glycyrrhizin
Description: apigenin will be administered as capsule (10mg,eq 200mg Matricaria chamomilla L extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glycyrrhizin and boswellic acid
Description: boswellic acid will be administered as capsule (200mg,eq 250mg Boswellia serrata extract) two times daily. Also, glycyrrhizin  will be administered as capsule(50 mg eq 250 mg licorice extract) two times daily. The two types of capsules administration will be continue for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo capsule will be administered two times daily for 6 months
Study: NCT05430230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: lactose NF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: lactose NF
Study: NCT05381194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPaL(M) regimen
Description: Patients diagnosed with MDR/RR-TB are initially assigned to the BPaLM regimen as a single-arm for treatment initiation. Afterward, if MDR/RR-TB is confirmed to be fluoroquinolone-resistant by molecular or phenotypic DST, the treatment is switched to the BPaL regimen (for 24 weeks). On the other hand, if MDR/RR-TB is confirmed to be fluoroquinolone-susceptible, treatment for MDR/RR-TB is maintained with the BPaLM regimen (for 26 weeks).~The dosage of each medication is as follows:~* Bedaquiline 400mg/day for the 2 weeks, 200mg/TIW afterward~* Pretomanid 200mg/day~* Linezolid 600mg/day for the 9weeks, 300mg/day afterward~* Moxifloxacin 400mg/day
Study: NCT02492074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol
Description: oral administration of delta-9-tetrahydrocannabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol
Description: oral administration of delta-9-tetrahydrocannabinol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: oral administration of cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: oral administration of cannabidiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral administration of placebo
Study: NCT06155331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: It is an approved drug for hypercholesterolemia, It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is made to look exactly like a real drug but is made of an inactive substance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Anthracycline derived chemotherapy used in treatment of breast cancer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Anthracycline derived chemotherapy used in treatment of breast cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Alkylating agent used in treatment of breast cancer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Alkylating agent used in treatment of breast cancer
Study: NCT04994990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA Standard Dose
Description: Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA Half Standard Dose
Description: Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA
Study: NCT04674384

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Optifast meal replacement shakes
Description: Optifast® is provided as 53g sachet. Each sachet replaces one meal. It is available in 5 flavours: vanilla, strawberry, chocolate and coffee shakes and vegetable soup.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Optifast meal replacement shakes
Description: Optifast® is provided as 53g sachet. Each sachet replaces one meal. It is available in 5 flavours: vanilla, strawberry, chocolate and coffee shakes and vegetable soup.
Study: NCT06363006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI+Cardunilimab
Description: Cardonilizumab 6mg/kg, IV, Q2W + lenvatinib 8mg (body weight \< 60kg) or 12mg(body weight ≥60kg) PO, QD, / Sorafenib 400mg, PO, BID/ Regorafenib 160mg, PO, QD/ Donafenib 200mg, PO, BID。 omniscience
Study: NCT05127889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curodont
Description: * To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~* The varnish will be mixed with the brush to avoid separation of the material during storage~* However, to guarantee the best results suction will be used during application of the varnish.~* A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~* The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~* After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs.
Study: NCT05883150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Midazolam
Description: All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child The sedative drug, the dosage will be diluted with an equal volume by adding distilled water.~The child will be seated in an upright position on the dental chair. Before placing the mask of the nebulizer, the child will be coached into proper breathing pattern

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Midazolam
Description: All the drug solutions will be freshly prepared on the day of sedation session. Depending on the dosage calculated from the weight of each child, For children who will receive midazolam using the atomization device attached to a three-ml syringe, the child sitting reclined in knee-to-knee position. Half of the dose will be sprayed in the right nostril and the other half will be sprayed in the left nostril to double the absorptive surface area by short and quick puffs
Study: NCT05532709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: m level one (weeks one and two; 1-2 sets of 10 repetitions) to level two (weeks three and four; 1-2 sets of 8 repetitions) and finally level three (weeks five and six; 1-2 sets of 6 repetitions). Plyometric training programs included both leg jumps, single-leg jumps, hurdle jumps, drop jumps, box jumps or lunge jumps

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training
Description: The circuit training consists of 6 exercises, divided in 2 blocks (1st block contains~½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes.
Study: NCT05434689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Corticosteroid active against multiple myeloma in combination with other agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Corticosteroid active against multiple myeloma in combination with other agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Second generation proteasome inhibitor with activity in multiple myeloma